Jim Tananbaum, Foresite Capital CEO (Business Wire)
June 29, 2021 10:25 AM EDTUpdated July 2, 01:36 PM
Financing
Deals

Gilead, Fore­site take an un­known pan­dem­ic an­tivi­ral pub­lic in $250M SPAC deal

Jason Mast

Editor

The SPAC boom has pro­duced some sur­pris­ing deals but gen­er­al­ly speak­ing, peo­ple fol­low­ing the in­dus­try have at least heard of the com­pa­nies go­ing pub­lic. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times